Advertisement
Advertisement
UPB
Upstream Bio, Inc. Common Stock
7.25
USDSponsored
+0.38
+5.53%
Aug 07, 15:59 UTC -4
Closed
After-Market
7.45
+0.20
+2.76%
UPB Earnings Reports
Positive Surprise Ratio
UPB beat 2 of 7 last estimates.
29%
Next Report
In 3 Days
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
$435.02K
/-$0.76
Implied change from Q1 26 (Revenue/ EPS)
-57.93%
/+1.33%
Implied change from Q2 25 (Revenue/ EPS)
-53.57%
/+2.70%
Upstream Bio, Inc. Common Stock earnings per share and revenue
On May 13, 2026, UPB reported earnings of -0.75 USD per share (EPS) for Q1 26, beating the estimate of -0.78 USD, resulting in a 3.98% surprise. Revenue reached 1.03 million, compared to an expected 446.42 thousand, with a 131.62% difference. The market reacted with a +4.58% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of -0.76 USD, with revenue projected to reach 435.02 thousand USD, implying an increase of 1.33% EPS, and decrease of -57.93% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
FAQ
What were Upstream Bio, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Upstream Bio, Inc. Common Stock reported EPS of -$0.75, beating estimates by 3.98%, and revenue of $1.03M, 131.62% above expectations.
How did the market react to Upstream Bio, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 4.58%, changed from $8.95 before the earnings release to $9.36 the day after.
When is Upstream Bio, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for Upstream Bio, Inc. Common Stock's next earnings report?
Based on 7
analysts, Upstream Bio, Inc. Common Stock is expected to report EPS of -$0.76 and revenue of $435.02K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement